Sunitinib

證據等級: L5

預測適應症: 10 個

Sunitinib: From Renal Cell Carcinoma to Liposarcoma

One-Sentence Summary

Sunitinib is a multi-targeted tyrosine kinase inhibitor already established globally for renal cell carcinoma, GIST, and pancreatic neuroendocrine tumours, though it is not currently marketed in Finland. The TxGNN model predicts it may also be effective for Liposarcoma, with 3 clinical trials and 9 publications currently supporting this direction. The same evidence pack also independently recovered sunitinib's known renal cell carcinoma activity (L1 evidence), which lends credibility to the model's less-established predictions.

Quick Overview

Item	Content
Original Indication	Not documented in Fimea licensing data (drug not marketed in Finland); literature within this evidence pack confirms sunitinib is a globally approved first-line therapy for advanced/metastatic renal cell carcinoma
Predicted New Indication	Liposarcoma
TxGNN Prediction Score	99.87%
Evidence Level	L2
Finland Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed structured mechanism-of-action data is not available for this drug entry. Based on information embedded in the trial and literature evidence collected for this pack, sunitinib is described repeatedly as a multitargeted receptor tyrosine kinase inhibitor, acting on VEGFR, PDGFR, and KIT, and working by "blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor" (NCT00474994). Its efficacy in VEGF/PDGFR-driven cancers such as renal cell carcinoma is well proven — reflected in this same evidence pack, where sunitinib appears as the historical standard-of-care comparator arm in numerous Phase 3 renal cell carcinoma trials (e.g., NCT00083889, NCT02231749, NCT03141177).

Soft tissue sarcomas, including several liposarcoma subtypes, frequently show PDGFR and VEGFR pathway activation, providing a plausible mechanistic bridge from the drug's proven anti-angiogenic/anti-proliferative activity in renal cell carcinoma to activity in liposarcoma. This is not a purely theoretical leap: two completed Phase 2 trials (NCT00400569, NCT00474994) already tested sunitinib directly in liposarcoma patients as part of broader soft-tissue-sarcoma cohorts, and a published case report (PMID 23482782) documents long-lasting clinical benefit in a heavily pre-treated metastatic liposarcoma patient.

That said, liposarcoma is histologically heterogeneous. Well-differentiated and dedifferentiated subtypes are predominantly MDM2-driven rather than PDGFR/VEGFR-driven, so sunitinib's activity is likely confined to specific subtypes (e.g., myxoid/round-cell liposarcoma) rather than the disease as a whole — a caveat the evidence pack itself flags.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00400569	Phase 2	Completed	48	Open-label single-site trial of sunitinib malate in adult patients with metastatic/unresectable soft tissue sarcoma, including liposarcoma, leiomyosarcoma, fibrosarcoma, and MFH
NCT00474994	Phase 2	Completed	53	Multicenter continuous-dosing sunitinib trial in non-GIST sarcomas (metastatic, locally advanced, or recurrent); liposarcoma among eligible histologies
NCT02048371	Phase 2	Completed	131	SARC024 basket study of oral regorafenib (not sunitinib) across sarcoma subtypes including liposarcoma; only indirectly relevant, cited as precedent for kinase-inhibitor activity in sarcomas

Literature Evidence

PMID	Year	Type	Journal	Key Findings
21154746	2011	Phase 2 trial	International Journal of Cancer	Phase 2 study of sunitinib malate in relapsed/refractory soft tissue sarcoma, with dedicated focus on leiomyosarcoma, liposarcoma, and MFH
23482782	2013	Case report	Anticancer Research	Long-lasting clinical benefit of sunitinib malate in a heavily pre-treated metastatic liposarcoma patient
38254762	2024	Review (genomic)	Cancers	Genetic, epigenetic, and transcriptomic alterations in liposarcoma relevant to target-therapy selection
24712007	2014	Review	Magyar Onkologia	Medical treatment of adult soft tissue sarcomas by histological subtype, including targeted-agent options
24555529	2014	Review	Expert Review of Anticancer Therapy	Emerging systemic therapies for adult soft tissue sarcoma
22987955	2012	Review	Annals of Oncology	Histology-driven medical treatment of soft tissue sarcomas, noting subtype-specific chemosensitivity
38717131	2024	Case series (pathology)	American Journal of Surgical Pathology	Clinicopathologic analysis of myxoid inflammatory myofibroblastic sarcoma, a related but distinct sarcoma entity
28423517	2017	Genomic profiling	Oncotarget	Next-generation sequencing of extraskeletal myxoid chondrosarcoma, evaluating predictors of sunitinib benefit
25884155	2015	Trial protocol (regorafenib)	BMC Cancer	REGOSARC protocol for regorafenib in advanced soft tissue sarcoma; different drug, cited for angiogenesis-pathway rationale only

Finland Market Information

Sunitinib is not currently marketed in Finland. No Fimea marketing authorizations are on record in this evidence pack (0 licenses), so no product-level dosage form or indication text is available.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (multi-targeted receptor tyrosine kinase inhibitor; VEGFR/PDGFR/KIT), not a conventional cytotoxic agent
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Given the drug class, standard practice for oral VEGFR-targeted TKIs includes CBC with differential, liver and renal function, and blood pressure/cardiac monitoring; exact thresholds pending Fimea package insert (data gap)
Handling Protection	Oral capsule formulation; standard oral antineoplastic handling precautions apply (avoid crushing/opening capsules); confirm against local hazardous-drug handling policy pending package insert

Safety Considerations

Please refer to the package insert for safety information. Fimea warnings, contraindications, and drug-interaction data are not yet available in this evidence pack (flagged as a Blocking data gap — see Conclusion).

Other Candidate Indications Identified in This TxGNN Run

This evidence pack scored ten candidate indications for sunitinib. For context, they are summarized below; only liposarcoma (rank 1) is detailed above.

Rank	Disease	TxGNN Score	Evidence Level	Decision
2	Ovarian myxoid liposarcoma	99.84%	L3	Research Question
3	RCC associated with neuroblastoma	99.78%	L5	Hold (trial linkage appears mismatched)
4	RCC with Xp11.2/TFE3 fusion	99.78%	L3	Research Question
5	Unclassified RCC	99.78%	L2	Proceed with Guardrails
6	Dermatofibrosarcoma protuberans	99.73%	L2	Proceed with Guardrails
7	Childhood kidney cell carcinoma	99.72%	L4	Research Question
8	Angiolipoma	99.67%	L5	Hold (benign, no systemic-therapy rationale)
9	Renal carcinoma	99.65%	L1	Proceed with Guardrails (already a globally approved indication, not a novel finding)
10	Heart fibrosarcoma	99.63%	L5	Hold (no evidence, cardiotoxicity concern with TKI use)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Two completed Phase 2 trials and a case report directly support sunitinib activity in liposarcoma, and the mechanistic link (VEGFR/PDGFR pathway) is grounded in evidence already present in this pack. However, liposarcoma's histological heterogeneity means benefit is likely subtype-specific, and no Finland-specific regulatory or safety data currently exist.

To proceed, the following is needed:

Fimea package insert warnings, contraindications, and full safety profile (currently a Blocking data gap)
Structured DrugBank mechanism-of-action data to formally confirm target/pathway claims
Subtype-level liposarcoma response data (e.g., myxoid/round-cell vs. well-differentiated/dedifferentiated) to refine the guardrails for patient selection
A regulatory pathway assessment given sunitinib is not currently marketed in Finland
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.